2- methyl- 3- (4- (3- pyridinylmethyl)phenyl)- 2- propenoic acid

Subscribe to Selected New Research on 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid

28 relevant articles (4 outcomes, 5 trials/studies) found for this Bio-Agent

Description: RN refers to (E)-isomer

Also Known As:

(E)-3-(4-(3-pyridlymethyl)phenyl)-2-methylacrylic acid; 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, sodium salt, (E)-isomer; 2-propenoic acid, 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-, hydrochloride; 3-(4-(3-pyridylmethyl)phenyl)-2-methyl-2-propenoic acid; OKY 1555; OKY 1580; OKY 1581; OKY-1581; beta-(4-(2-carboxy-1-propenyl)benzyl)pyridine; sodium (E)-3-(4-(3-pyridylmethyl)phenyl)-2-methylacrylate; 2-propenoic acid, 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-,

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid: 28

Related Diseases

1.	Thrombosis (Thrombus) 01/01/1987 - "The effects of acetylsalicylic acid alone, of acetylsalicylic acid plus dipyridamole, and OKY 1581 may be due to inhibition of platelet aggregation and intraglomerular thrombosis, with the fall in BP being the consequence of improved renal function" 06/01/1985 - "The results in terms of thrombus prevention were as follows: controls congruent to Tris-HCl buffer less than OKY-1581 congruent to low dose PGI2 less than high dose PGI2 less than heparin" 05/01/1992 - "Neither benidipine (3-30 micrograms/kg, i.v.) nor nicardipine (100 micrograms/kg, i.v.) inhibited the AgNO3-induced thrombus formation of the abdominal aorta, whereas ticlopidine (100 mg/kg, p.o.) and OKY-1581 (3 mg/kg, i.v.) prevented the thrombus formation" 01/01/1986 - "The importance of the thrombus formation in the rejection process was further strengthened by prolongation of the cessation of the blood flow at the boundary from day 10 to days 14-15, after daily administration from days 2 to 9 of OKY-1581 (0.4 mg/g i.p.), a selective thromboxane synthetase inhibitor, or ticlopidine (0.3 mg/10 g p.o.), an inhibitor of platelet aggregation, in combination with a subthreshold dose (0.4 mg/10 g i.p.) of azathioprine" 06/01/1985 - "In the present study, a recently developed model of carotid endarterectomy in rats was used to assess the effectiveness of heparin, prostacyclin (PGI2), and OKY-1581, a selective thromboxane A2 (TXA2) synthetase inhibitor, in preventing thrombus formation" Get all the results and reference details, order at left...
2.	Hypotension (Low Blood Pressure) 06/01/1984 - "rCBF responses to intravenous OKY-1581 fell into 3 categories: A) no change in rCBF, B) decrease in rCBF related to MABP and C) increase in rCBF in the presence of hypotension" 03/01/1985 - "The degree of systemic hypotension observed with arachidonic acid infusions was significantly greater in animals receiving OKY-1581 than in animals without the inhibitor" 06/01/1982 - "All of the hypertensive phase and 100 - 150% of the increase of the airway resistance by LTC4 and LTD4 were inhibited by a selective thromboxane synthetase inhibitor, OKY-1581 (10 mg/kg, i.v.) and only the hypotension was observed" Get all the results and reference details, order at left...
3.	Intracranial Vasospasm 06/01/1984 - "While the results do not support a major role for TXA2 in cerebral vasospasm pathogenesis, OKY-1581 may still be useful in the treatment of cerebral vasospasm, as it improves distal and deep circulation and inhibits platelet aggregation." 07/01/1982 - "Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581." 07/01/1982 - "The above results indicate that a disproportionate synthesis of thromboxane A2 plays an important role in the evolution of chronic cerebral vasospasm following SAH, and that drugs such as OKY-1581 that selectively inhibit thromboxane synthetase might be useful in the prevention of vasospasm." Get all the results and reference details, order at left...
4.	Myocardial Infarction 07/01/1985 - "To evaluate the efficacy of selective thromboxane A2 blockade on diminution of propagating acute myocardial infarction, another group of patients (24 cases) showing transmural myocardial infarction were subjected to therapeutic examination employing OKY-1581, a potent thromboxane A2 synthetase inhibitor" Get all the results and reference details, order at left...
5.	Necrosis 01/01/1984 - "This study demonstrates that the suppression of thromboxane biosynthesis by OKY-1581, a selective inhibitor of thromboxane biosynthesis, prevents dose-dependently taurocholate-induced gastric mucosal necrosis and enhances the cytoprotective effect of low dose of taurocholate against mucosal necrosis by large dose of this agent" 03/01/1988 - "Whereas prostacyclin or OKY 1581 given shortly after acetaminophen prevented mortality and reduced liver necrosis, as assessed by serum ALT activity and histology, benzyl imidazole was only effective if given prior to acetaminophen" 02/01/1983 - "OKY-1581 prevented, dose dependently, the formation of taurocholate- but not ethanol-induced gastric necrosis, and this effect was accompanied by an increase in gastric mucosal generation of prostaglandin E2 and I2-like activity and a reduction in the thromboxane generation during platelet aggregation" Get all the results and reference details, order at left...
23 Diseases and 28 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Thromboxane A2 (A2, Thromboxane)
2.	Thromboxane-A Synthase
3.	Arachidonic Acid (Vitamin F)
4.	Dipyridamole (Persantine)
5.	Aspirin (Acetylsalicylic Acid)
6.	Epoprostenol (Prostacyclin)
7.	Ligases
8.	imidazole
9.	Taurocholic Acid (Sodium Taurocholate)
10.	Heparin (Liquaemin)
28 Drugs and Important Bio-Agents and 24 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Carotid Endarterectomy
2.	Nephrectomy
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>